Sirnaomics (HKG:2257) dosed the first patient in a phase II clinical trial of STP705 for aesthetic applications, according to a Thursday Hong Kong bourse filing.
The product has been developed to deliver a minimally-invasive therapeutic alternative to conventional fat-reduction interventions.